Browsing by Author Levchenko, Evgeny

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2017Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyLong, Georgina; De Braud, Filippo; et al, Various; Flaherty, K; Garbe, C; Gogas, Helen; Hauschild, Axel; Jouary, Thomas; Larkin, J; Levchenko, Evgeny; Stroyakovskiy, Daniil; Northern Clinical School: MedicineDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study, Annals of Oncology, vol.28, 7, 2017,pp 1631-1639
2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaLong, Georgina; Amonkar, Mayur M; Bondarenko, Igor; de Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Lebbe, Celeste; Levchenko, Evgeny; Schadendorf, Dirk; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, European Journal of Cancer, vol.51, 7, 2015,pp 833-840
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55